ReviewHeliyon2022
Calcitonin gene-related peptide is potential therapeutic target of osteoporosis.
Review in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Application and prospects of nanomaterials in osteoporosis treatment.International journal of pharmaceutics: X · 2026Review
- Mitochondria-targeted delivery strategies for age-related diseases.International journal of pharmaceutics: X · 2026Review
- The role of the neuro-immune-bone axis in osteoporosis: from bone remodeling imbalance to multi-system interactions.Frontiers in immunology · 2026Review
- Up-regulation of peripheral and central CGRP expression combined with subchondral bone remodeling in rat MIA-induced TMJOA model.Journal of oral & facial pain and headache · 2025Article
- Aging and Thymosin Alpha-1.International journal of molecular sciences · 2025Review
- Yam polysaccharide promoted bone differentiation of MC3T3-E1 cells through targeted Inhibition of CASP3 activation.Journal of orthopaedic surgery and research · 2025Article
- Adenovirus mediated gene delivery of α-calcitonin gene-related peptide facilitates osseointegration of implant in ovariectomized rat.Regenerative therapy · 2025Article
- The effects of alfacalcidol combined with calcitonin in the treatment of osteoporosis and its influence on levels of inflammation.American journal of translational research · 2024Article
- The Effect of Group Training or Spinal Orthosis on Quality of Life and Potential Plasma Markers of Pain in Older Women With Osteoporosis. A Randomized Controlled Trial.Archives of rehabilitation research and clinical translation · 2023Article
- Bone-Targeted Delivery of Cell-Penetrating-RUNX2 Fusion Protein in Osteoporosis Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Review
- RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a skeletal disorder characterised by the decrease of bone mineral density and is becoming prevalent with the entry of an ageing era. There are two catalogues of osteoporosis, including primary osteoporosis and secondary osteoporosis, according to the pathological causes. Since the demonstrations of osteoporosis are usually covered by other diseases, its therapeutic strategies are not satisfactory for both patients and clinicians. Calcitonin gene-related peptide (CGRP) is a peptide expressed in both bone tissues and peripheral nerves innervating bone tissue, and its expression in osteoporosis patients is increased. Recent studies have indicated that CGRP could promote the osteogenesis by osteblasts and bone absorption by osteoclasts, thus maintaining the bone homeostasis. The effects of CGRP on bone homeostasis are related with its promotion of angiogenesis through vascular endothelial growth factor and its modulation of multiple signal pathways including receptor activator of nuclear factor kappa-Β ligand. In addition, CGRP could interact with neuronal system through neural growth factor to modulate osteoporosis. Application of implants or nanoparticles also verified the beneficial effect of CGRP on osteoporosis. There studies imply a great therapeutic potential of CGRP in treating osteoporosis. Although massive studies about CGRP in osteoporosis have been performed with positive results, there is little development in clinical application. The review summarises recent advancement in the roles of CGRP in modulating osteoporosis, which will be helpful in providing some directions for further study of CGRP in treating osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.